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Background: Deep brain stimulation (DBS) has become a preferred option for the 
treatment of motor symptoms in patients with advanced Parkinson’s disease (PD). A 
good levodopa response (LR) is considered the most important criterion in determining 
the suitability of a patient for DBS. However, the effect of age and disease duration (DD) 
on the LR is still a subject of discussion.
Objective: Here, we investigated the effect of age and DD on the preoperative LR in PD 
patients to be selected for DBS.
Methods: From August 2011 to May 2015, 54 consecutive patients (29 men and 25 
women) with advanced PD were evaluated for DBS of the STN and included in this 
retrospective study.
results: Thirty-seven patients were found suitable for DBS of the STN and 29 of them 
underwent bilateral surgery. We found no significant correlation between DD and the 
LR. However, there was a significant negative correlation between the patients’ age and 
the LR.
conclusion: The results indicate that the patients’ age, rather than DD, has a negative 
effect on the LR. The study, therefore, indicates that PD patients with an advanced age 
and with a poor LR are not good candidates for DBS of the STN.
Keywords: Parkinson’s disease, deep brain stimulation, levodopa response, age, disease duration, subthalamic 
nucleus
inTrODUcTiOn
Parkinson’s disease (PD) is a chronic neurodegenerative disorder primarily characterized by progres-
sive motor impairments due to dopamine insufficiency. As the disease progresses, levodopa-related 
motor complications develop (1). At this stage, it is difficult to treat PD patients with dopaminergic 
medications. Deep brain stimulation (DBS) is an effective option for the treatment of motor symp-
toms in patients with advanced PD (2). The success of DBS is mainly dependent on the selection 
of the patients suited for this treatment, who could thus have a better benefit-to-risk ratio. A good 
levodopa response (LR), corresponding to >30% improvement according to the Unified Parkinson’s 
TaBle 1 | Data of the 54 cases of the present study.
clinical data Quantitative data
Age: years; mean ± SD 55.62 ± 9.4
Sex: female/male; n (%) 25/29 (46.3/53.7)
Subtypes: TD/TND; n (%) 25/29 (46.3/53.7)
Disease duration: years; mean ± SD 10.68 ± 5.3
Levodopa response: total (%; mean ± SD) 46.73 ± 20.4
Levodopa response: TD/NTD (%; mean ± SD) 49.78 ± 18/44.10 ± 21a
HY OFFb: ≥ 3 n (%) 45 (83.3)
Suitable for DBS of the STN n (%) 37 (68.5)
DBS of the STN performed (%) 30 (55.5)
Motor improvement at the third monthc (%; mean ± SD) 54.4 ± 17.9
aNo difference between the motor subtypes in the levodopa response.
bOFF period: the period of at least 12 h after the last levodopa dose.
cMotor improvement at the third month: the response to stimulation (stim) ON-
medication (med) OFF when compared with stim OFF-med OFF in 24 patients.
HY, Hoehn and Yahr; TD, tremor-dominant; NTD, non-tremor dominant; STN DBS, 
subthalamic nucleus deep brain stimulation.
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Disease Rating Scale part (UPDRS) Part III score, is currently 
the most important criterion in determining the suitability of a 
patient for DBS (3, 4), because it is known that only PD patients 
who have a good LR can benefit from DBS.
To the best of our knowledge, the effect of age and disease 
duration (DD) on the LR in patients with advanced PD has not 
been investigated in detail up to now. The American Academy 
of Neurology has reported that DD and age have an effect on 
the outcome of DBS (5). Durso et al. (6) have reported that the 
effect of age on the LR in PD is adverse. A study of patients with 
early PD has pointed out that DD has a negative effect on the 
LR (7). Similarly, it has been suggested that the long-duration 
response to levodopa eventually becomes ineffective with disease 
progression (8). These data suggest that the LR decreases as the 
disease advances.
In contrast to the abovementioned studies, Ganga et  al. (9) 
showed that the magnitude of LR did not decrease significantly in 
PD patients at the end of a mean follow-up of 18.2 years. Similarly, 
Wider et  al. (10) suggested that the long-duration response to 
levodopa remains significant even in advanced PD. Thus, the 
effects of age and DD on the LR are currently debated.
Here, we report the effect of age and DD on the LR in patients 
with advanced PD evaluated for DBS of the subthalamic nucleus 
(STN). We addressed the question as to whether the preoperative 
LR correlates with age and DD.
MaTerials anD MeThODs
subjects
This retrospective study was approved by the Local Ethics 
Committee of our University. It was registered in the registry of 
our University (registration number 2015/121). From August 
2011 to May 2015 (a period of 46  months), 54 consecutive 
patients with advanced PD (all patients except 2 had a DD longer 
than 5  years) evaluated for DBS were included in this study. 
Diagnosis of PD was based on the United Kingdom Parkinson’s 
Disease Society Brain Bank Clinical Diagnostic Criteria as 
bradykinesia in association with rest tremor, rigidity, or postural 
instability (11). All PD patients were assessed by a neurologist 
(Dursun Aygun) experienced in movement disorders. From all 
patients and their families, a detailed history of the demographic 
features of the patients and the motor and non-motor symptoms 
of PD, including rapid eye movement (REM) sleep behavior 
disorder (RBD), was obtained. Thus, DD and age for all patients 
were identified from this detailed disease history. Their clinical 
motor symptoms were assessed before DBS by the UPDRS III 
in both OFF (at least 12 h after the last levodopa dose) and ON 
medication states (12). The UPDRS III in the “ON” condition 
was obtained 40–60  min after administration of 1.5 times the 
optimal morning dose of levodopa. The LR rates of the patients 
were thus determined on the basis of the difference between the 
UPDRS III scores in the OFF and ON medication states. Both the 
Core Assessment Program for Surgical Interventional Therapies 
in PD (CAPSIT-PD) and the Florida Surgical Questionnaire 
for Parkinson Disease (FLASQ-PD) criteria were used to select 
patients suited for STN DBS (3, 13). All the patients had a history 
of both positive response to levodopa and a positive LR during 
follow-up; however, we only applied DBS surgery to those whose 
LR was over 30%. All data of the PD patients were recorded and 
saved on an electronic file.
We applied the following inclusion criteria: (1) clinical diag-
nosis of idiopathic PD (11) and (2) adult age (older than 18 years) 
and the following exclusion criteria: (1) patients whose history of 
DD and age were unclear, (2) patients who were not evaluated for 
STN DBS, and (3) patients whose initial symptoms could not be 
determined from their history.
The patients were classified as belonging to the tremor-
dominant (TD) or non-tremor-dominant (NTD) PD subtypes. 
When tremors were seen at the disease onset as the sole initial 
symptom, the patients were included in the TD subtype (14, 15). 
The patients with TD had, as expected, a higher tremor score 
than the scores for bradykinesia and rigidity of UPDRS in the 
OFF medication state (9). If tremor and bradykinesia/rigidity 
scores were equal, the clinical descriptions by the patient and 
patient’s family were used to determine the dominant motor 
signs (9).
statistical analysis
Data are presented as mean ±  SD. The SPSS Version 15.0 was 
used for the statistical analysis. Because of the non-normally 
distributed data, differences between the groups were analyzed by 
non-parametric tests. The correlations between age and DD with 
the LR were investigated using the Spearman’s ρ correlation test. 
The Mann–Whitney U test was used to compare the LR between 
motor subtypes. A value of p  <  0.05 was set as significance 
threshold.
resUlTs
All of the patients met the inclusion and exclusion criteria of 
the study. The DBS was applied bilaterally in 30 of 54 patients 
with PD (29 men and 25 women, Table 1). Seven of the patients 
were subjected to DBS surgery after the completion of this study. 
The DBS surgery was not applied to 17 patients (31.48%) who 
FigUre 3 | scatter plot of the relationship between disease duration 
and the preoperative levodopa response (lr) in the different cases. 
The line indicates the average value.
FigUre 2 | scatter plot of the correlation between age and the 
preoperative levodopa response (lr). The line indicates a negative 
correlation (r = −0.374; p = 0.013).
FigUre 1 | Preoperative levodopa response in the motor subtypes of 
Parkinson’s disease in this study (*p > 0.05). Abbreviations: DD, disease 
duration; LR, levodopa response; NTD, non-tremor dominant; TD, tremor 
dominant.
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did not meet the criteria of the CAPSIT-PD. Thus, 37 patients 
(68.51%) were found suitable for STN DBS (Table  1). Mean 
age was 55.62 ±  9.4  years (a range of 34–74  years). Mean DD 
was 10.68 ± 5.3 years (a range of 3–30 years). All except two of 
our patients evaluated for DBS had a DD longer than 5  years. 
The LR rates ranged between 7.9 and 8.8%, with an average of 
46.73 ±  20%. The number of the patients in the Hoehn and 
Yahr stage ≥3 in the OFF state was 45 (83.3%) (Table 1). Of the 
patients, 53.7% (n = 29) were included in the NTD subtype and 
46.3% (n = 25) in the TD subtype (Table 1). The Hoehn and Yahr 
stage, DD, and age did not differ between the subtypes.
There was no significant correlation between DD and the 
preoperative LR [correlation coefficient (r) = −0.103; p = 0.510] 
(Figure 1). However, there was a significant negative correlation 
between age and the preoperative LR (r = −0.374; p =  0.013) 
(Figure  2). There was no difference between the motor sub-
types concerning the LR (Table  1; Figure  3). The effect of 
DBS in all patients after surgery was over 50%. For example, 
the motor improvement at the third month of 24 patients 
was  54.4 ±  17.9%, representing the response to stimulation 
ON/medication OFF condition when compared with stimula-
tion OFF/medication OFF condition. There were no irrevers-
ible complications in the peri- and postoperative period of the 
patients who underwent STN DBS.
DiscUssiOn
Here, we found that DD had no significant effect on the LR, 
while we identified a negative correlation between age and the 
preoperative LR. To the best of our knowledge, this is the first 
report on the effect of age, DD, and motor subtypes on the LR in 
patients with advanced PD.
Limitations of this study are the small size of the patients’ 
cohorts and the retrospective nature of the methodological 
design. However, it should be considered that all the preopera-
tive and postoperative data of each patient have been carefully 
recorded by a neurologist expert in movement disorders.
Concerning the available literature, Ganga et al. (9) assessed 
the LR in PD during a mean 18.2-year study period (range: 
14.4–21.8 years) and found that there was no significant differ-
ence in the amplitude of LR between motor subtypes (i.e., TD 
and TND) (9). They (9) also showed that the magnitude of LR 
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did not decrease significantly at the end of the study period. 
Thus, such findings (9) support our data that motor subtypes 
and DD have no significant effect on the LR in PD. Another 
study (10) compared the postoperative and preoperative UPDRS 
III scores in 30 patients with STN DBS and suggested that the 
long-duration response to levodopa remained significant even in 
advanced PD, and that DBS of the STN compensated the LR (10). 
The results of the two abovementioned studies (9, 10) support 
the conclusion of our study that DD has no significant effect 
on the LR. Durso et al. (6) suggested that in PD patients treated 
long term, age has a stronger adverse influence than DD on the 
magnitude of the LR. Our study is, therefore, supported by such 
conclusions (6).
It is known that PD patients have a better response to levodopa 
than those with Parkinson plus syndromes (PPS) and that this 
poor LR in PPS is associated with pre- and postsynaptic dopa-
mine cell degeneration. In PPS, the striatum is involved early and 
severely (16–18). 11C-raclopride positron emission tomography 
(PET) studies have shown that there is no decrease in binding 
to the postsynaptic striatal dopamine D2 receptors in patients 
with PD, which is increased or normal (16). This condition, 
considered to be a compensatory reaction to the loss of the 
nigrostriatal dopaminergic neurons, corresponds to postsynaptic 
striatal dopamine D2 receptor upregulation (16). The presence 
of postsynaptic degeneration (i.e., reduced striatal D2 receptor 
uptake or striatal hypometabolism) in PPS, in contrast to PD, has 
been shown in studies using striatal functional imaging, such as 
11C-raclopride PET, 123I-IBZM SPECT, and FDG-PET (16–19). By 
means of 18F-DOPA, it has been shown that the loss of nigrostri-
atal dopaminergic terminals is more severe in PPS than in PD 
(20). Thus, PPS are refractory to levodopa treatment, whereas the 
benefit of levodopa treatment in PD can still persist in the later 
stages of disease due to striatal D2 receptor upregulation (16, 17). 
Thus, it is likely that, in PD, the LR is not significantly influenced 
by DD.
Taken together, these literature data support our finding that 
DD in PD has no significant effect on the LR. However, we have 
identified, in this study, a significant correlation between age and 
preoperative LR. The negative effect of age on the LR could be due 
to a slowdown in the striatal postsynaptic D2 receptor upregula-
tion with increasing age in PD.
In contrast to the abovementioned studies, the results of other 
studies have pointed to the presence of prominent negative effects 
on the LR of DD (7, 8, 21). Espay et al. (7) have reported that DBS 
of the STN performed in “early” PD confers a greater quality-
adjusted life expectancy than delayed surgery. It is well known 
that only PD patients who have a good LR can benefit from DBS. 
On the other hand, in patients at an earlier stage of PD, DD is 
obviously shorter than in those with advanced disease. Hence, it 
has been reported that patients with shorter DD respond better 
to levodopa than those with longer DD (7). These results point 
to an inverse correlation between DD and LR. Accordingly, it 
has been suggested that the long-term LR is gradually reduced 
with disease progression (8). A long-term follow-up study (21) 
has revealed a progressive worsening of UPDRS III motor score 
in the “stimulation OFF/medication ON” conditions over time 
(21). This indicated a relationship between LR and DD (21), 
which appears in conflict with thus study, despite the fact that 
the methodology for determining the LR (21) was similar to that 
we adopted in our study. However, we adopted a different meth-
odology for the assessment of the relationship between the LR 
and DD, since, at variance with such previous investigation (21), 
we here compared directly these parameters. Merello et al. (22) 
assessed the sensitivity and specificity of an acute challenge with 
levodopa to predict sustained long-term levodopa responsiveness 
in PD. They observed that the sensitivity was lowest in patients 
with initial UPDRS III score ≥21 (22). These findings may imply 
that the sensitivity to acute levodopa challenge decreases as the 
disease stage advances, suggesting that the LR decreases as the 
disease advances.
All these sets of data could indicate that patients with a 
longer DD have a lower LR, than those with a shorter DD. 
Although we did not find a correlation between DD and LR, 
supporting previous studies (9, 10), our data show that DD 
exerts a much lower adverse influence than age on the LR, in 
agreement with Durso et al.’s findings (6). Such lower adverse 
influence of DD on LR could be associated with the progression 
of disease stage. However, the disease progression rate shows 
high interindividual variability. For example, while some PD 
patients rapidly develop movement difficulties, others may 
have mild symptoms for a relatively long time, which could be 
reflected in studies of patients’ populations. The effect of age 
and DD on the LR is an ongoing discussion topic. However, 
Albanese et  al. (23) have reported that, with the appropriate 
indication and setting, acute challenge tests are useful in diag-
nosis and therapy of PD.
cOnclUsiOn
In this study, we found that DD has no significant effect on the LR, 
and we show, instead, a significant negative correlation between 
age and LR, as supported by a previous study (6). Our findings 
suggest that patients with longer DD, but not advanced age, still 
benefit from DBS. Additionally, we found that there is no differ-
ence between motor subtypes concerning the LR.
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